Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

Gluz, Oleg; Kolberg‐Liedtke, Cornelia; Marmé, Frederik; Thill, Marc

doi:10.1055/a-1126-4247

Cited by 2 publications

(1 citation statement)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, it can significantly improve the survival rate of patients and has become a key drug for the treatment of advanced breast cancer [ 12 , 13 ]. PTX primarily acts by disrupting the cell division mediated by microtubules which function as tracks for axonal transport, and PTX can effectively interrupt this process, thereby resulting in CIPN [ 14 ]. CIPN is usually initiated with paresthesia, which is a lesser degree of pain in the extremities [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer

Guo

Zhang

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most common malignancies affecting women and the leading cause of related mortality worldwide. An estimated 2260000 new cases of BC were diagnosed in 2020, which have seriously threatened the health. Paclitaxel (PTX), a natural product isolated from the bark of the pacific yew, has been found to be effective in treating advanced BC. Chemotherapy-induced peripheral neuropathy (CIPN), which refers to the damage to the peripheral nerves caused by exposure to a neurotoxic chemotherapeutic agent, is a common side effect affecting the patients undergoing PTX chemotherapy. Significant research efforts are needed to identify the various risk factors associated with CIPN. Here, a univariate analysis in BC patients with nanonab-PTX treatment was performed. The rate of CIPN in BC patients with albumin-bound paclitaxel (nab-PTX) for more than four weeks was significantly higher than that of patients with chemotherapy for less than four weeks. Moreover, the rate of CIPN in BC patients receiving nab-PTX first-line chemotherapy was remarkably higher than that in BC patients receiving paclitaxel as a sequence scheme. Taken together, chemotherapy cycles and the priority of nab-PTX-based chemotherapy can be considered the potential risk factors for CIPN induced by nab-PTX.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer

Guo

Zhang

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

An up-to-date view of paclitaxel-induced peripheral neuropathy

Wu,

Xiong,

Guo

et al. 2023

Journal of Cancer Research and Therapeutics

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN),referring to the damage to the peripheral nerves caused by exposure to a neurotoxic chemotherapeutic agent, is a common side effect amongst patients undergoing chemotherapy. Paclitaxel-induced peripheral neuropathy (PIPN) can lead to dose reduction or early cessation of chemotherapy, which is not conducive to patients’survival. Even after treatment is discontinued, PIPN symptoms carried a greater risk of worsening and plagued the patient’s life, leading to long-term morbidity in survivors. Here, we summarize the research progress for clinical manifestations, risk factors, pathogenesis, prevention and treatment of PIPN, so as to embark on the path of preventing PIPN with prolongation of patient’s life quality on a long-term basis.

show abstract

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

Cited by 2 publications

References 65 publications

Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer

Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer

An up-to-date view of paclitaxel-induced peripheral neuropathy

Contact Info

Product

Resources

About